Z 944

All tissues were perfused continuously with KRB solution containing (mmol/L): NaCl, 5.9; NaHCO₃, 120.35; KCl, 1.2; MgCl₂, 15.5; NaH₂PO₄,1.2; CaCl₂, 2.5; and glucose, 11.5. The KRB solution was warmed to a physiological temperature of 37 ± 0.3°C and bubbled with a mixture of 97% O₂ – 3% CO₂. For experiments utilizing external solutions with 0 [Ca²⁺]_o, CaCl₂ was omitted and 0.5 mM ethylene glycol-bis (β-aminoethyl ether)-N, N, N’, N’–tetraacetic acid (EGTA) was added to the solution. NNC 55–0396 and TTA-A2 were purchased from Alomone Labs (Jerusalem, Israel). 2-aminoethyl-diphenylborinate (2-APB), tetracaine, nicardipine, pinacidil was purchased from Millipore-Sigma (St. Louis, Missouri, USA). Thapsigargin, isradipine, Z-944, CPA and ryanodine were purchased from Tocris Bioscience (Ellisville, Missouri, USA). GSK 7975A was purchased from Aobious (Aobious INC, MA, USA), and xestospongin C (XeC) was purchased from Cayman Chemical (Michigan, USA).

The following drugs were used in the present studies: ZD7288, U0126, MRS 1845, Z944 and RTX were purchased from Tocris (Ellisville, MO); ivabradine hydrochloride, nifedipine and sulpride from Sigma/RBI (St. Louis, MO); dantrolene and 2-APB from Santa Cruz Biotechnology (Dallas, TX). Palonosetron and netupitant were kindly provided by Helsinn Health Care (Lugano, Switzerland).
ZD7288, ivabradine hydrochloride and palonosetron were dissolved in water. Nifedipine, U0126, MRS 1845, Z944, dantrolene and 2-APB were dissolved in 25% DMSO in water. Netupitant and RTX were dissolved in a mixture of ethanol/Tween 80/saline at a volume ratio of 1:1:18. Sulpride was dissolved in distilled water with a 10 µL volume of 1/3 concentrated HCl which was then back titrated to pH 5 by the addition of NaOH. All drugs were administered at a volume of 0.1 ml/10 g of body weight.